NASDAQ:FLXN
Delisted
Flexion Therapeutics Stock News
$9.12
+0 (+0%)
At Close: May 27, 2022
Zacks: Analysts Anticipate Flexion Therapeutics Inc (NASDAQ:FLXN) to Announce -$0.91 Earnings Per Share
10:04am, Monday, 06'th Apr 2020
Brokerages expect that Flexion Therapeutics Inc (NASDAQ:FLXN) will report earnings per share (EPS) of ($0.91) for the current quarter, according to Zacks Investment Research. Two analysts have made es
Week In Review: Signs Of Life After Coronavirus - China Biopharma Scores $721 Million In Deals
03:58pm, Sunday, 05'th Apr 2020
Ping An announced a $311 million agreement with Japan's Shionogi to develop new drugs for infectious diseases and CNS needs based on Ping An's lifestyle data. H
Flexion Therapeutics (NASDAQ:FLXN) Stock Rating Reaffirmed by Needham & Company LLC
08:50am, Sunday, 05'th Apr 2020
Needham & Company LLC reiterated their buy rating on shares of Flexion Therapeutics (NASDAQ:FLXN) in a research report sent to investors on Wednesday morning, AnalystRatings.com reports. Needham & Com
Analysts Anticipate Flexion Therapeutics Inc (NASDAQ:FLXN) Will Post Quarterly Sales of $23.73 Million
08:10am, Sunday, 05'th Apr 2020
Wall Street analysts forecast that Flexion Therapeutics Inc (NASDAQ:FLXN) will report $23.73 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for F
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30pm, Friday, 03'rd Apr 2020
BURLINGTON, Mass., April 03, 2020 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to seven new employees consisting of 9,265 restricted.
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30pm, Friday, 03'rd Apr 2020
BURLINGTON, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to seven new...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 56'5(c)(4)
12:00am, Friday, 03'rd Apr 2020Benchmark Maintains Buy on Flexion Therapeutics, Lowers Price Target to $17
12:00am, Thursday, 02'nd Apr 2020Needham Thinks Flexion Therapeutics' Stock is Going to Recover
03:21pm, Wednesday, 01'st Apr 2020
In a report released today, Serge Belanger from Needham maintained a Buy rating on Flexion Therapeutics (FLXN), with a price target of $36.00. The
Needham Thinks Flexion Therapeutics’ Stock is Going to Recover
03:21pm, Wednesday, 01'st Apr 2020
In a report released today,
Serge Belanger
from Needham maintained a
Buy
rating on Flexion Therapeutics (
FLXN
–
Research Report
), with a price target of
$36.00
. The company’s shares closed last
Northland Securities Thinks Flexion Therapeutics' Stock is Going to Recover
01:01pm, Wednesday, 01'st Apr 2020
In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Flexion Therapeutics (FLXN), with a price target of $35.00.
Northland Securities Thinks Flexion Therapeutics’ Stock is Going to Recover
01:01pm, Wednesday, 01'st Apr 2020
In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Flexion Therapeutics (FLXN – Research
Flexion out-licenses Zilretta in China
11:29am, Wednesday, 01'st Apr 2020
Flexion Therapeutics (NASDAQ:FLXN) inks an agreement with HK Tainuo and China Shijiazhuang Pharmaceutical Co., Ltd. subsidiary Jiangsu Tainuo for the development and commercialization of Zilretta (tri
Flexion Therapeutics Announces ZILRETTA® License Agreement and Provides Business Update Amid Coronavirus Pandemic
11:00am, Wednesday, 01'st Apr 2020
Company signs exclusive license agreement with Hong Kong Tainuo Pharma Ltd. (HK Tainuo) and Jiangsu Tainuo Pharmaceutical Co. Ltd. (Jiangsu Tainuo) for the development and.
Credit Suisse AG Reduces Position in Flexion Therapeutics Inc (NASDAQ:FLXN)
10:20am, Wednesday, 01'st Apr 2020
Credit Suisse AG lessened its stake in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 96.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fi
